Abstract: The subject matter disclosed herein relates to obtaining position fixes using a position determination method in response to a change in an RF environment.

Abstract: Methods and apparatus for time synchronization and measurement of power distribution systems. A method includes receiving a synchronized wireless communication signal, synchronizing to the synchronized wireless communication signal to produce synchronized time, performing one or more power distribution measurements based on the synchronized time to produce synchronized power distribution measurements, and transmitting the synchronized power distribution measurements to a power control center. An apparatus includes a receiver configured to receive a synchronized wireless communication signal and to synchronize to the synchronized wireless communication signal to produce synchronized time, a measurement module configured to perform one or more power distribution measurements based on the synchronized time to produce synchronized power distribution measurements, and a transmitter configured to transmit the synchronized power distribution measurements to a power control center.

Abstract: A system and method for providing multimedia content between a plurality of user terminals is presented. A first multimedia presentation on a first user terminal is selected by a first user. Data corresponding to the first multimedia presentation is transmitted to a second user terminal. Data is received corresponding to a second multimedia presentation from the second user terminal by the first user terminal. The first multimedia presentation or the second multimedia presentation is displayed on the first user terminal and the second user terminal based on, respectively, a first profile of the first user terminal and a second profile of the second user terminal.

Abstract: At least one multimedia presentation is selected by a user of a first device, accessed from a storage source, and presented to the user. Simultaneously, information is transmitted to at least a second device to cause the selected multimedia presentation to be presented by the at least second device without the at least second device receiving input from a second user. Continuous media streams from the first user may be captured and transmitted to the second device. The presenting of the multimedia presentation on the first device is coordinated with the presenting of the multimedia presentation on the second device. The presenting of the captured media streams on the second device is coordinated with the capturing of those streams and the presenting of the multimedia presentation on the second device. Users may individually control the multimedia presentations and the captured media streams.

Abstract: An implementation of a system, device and method for communicating location data of a mobile station, enhancing location data, optimally communicating Assistance Data, and/or reducing rebids of Measure Position Request messages in a wireless network.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Abstract: Two color transformations, as described herein, facilitate identification of the objects of interest in the biological specimen. One of the color transformations, a Minus Clear Plus One (MC+1) transformation, can be conceptualized as either translating and rotating axes of a three-dimensional coordinate space that defines an image of the biological specimen or calculating differences between vectors in the three dimensional coordinate space that defines the image of the biological specimen. The other of the color transformations, a Quantitative Chromatic Transformation (QCT), is a calorimetric transformation that produces three new quantities from the original red, green, and blue pixel values for each color pixel of an image. These three new quantities, X, Y, and Z can each be related to the quantitative amount of absorbing molecules sampled by that pixel.

Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.

Abstract: A method and apparatus for automated cell analysis of biological specimens automatically scans at a low magnification to acquire images which are analyzed to determine candidate cell objects of interest. The low magnification images are converted from a first color space to a second color space. The color space converted image is then filtered. The candidate interest pixels are morphologically processed and compared to blob parameters to identify candidate objects of interest which correspond to cells or other structures relevant to medical diagnosis of the biological specimen. The location coordinates of the objects of interest are stored and additional images of the candidate cell objects are acquired at high magnification.

Abstract: A method, system, and apparatus are provided for automated light microscopic for detection of proteins associated with cell proliferative disorders.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.

Abstract: Two color transformations, as described herein, facilitate identification of the objects of interest in the biological specimen. One of the color transformations, a Minus Clear Plus One (MC+1) transformation, can be conceptualized as either translating and rotating axes of a three-dimensional coordinate space that defines an image of the biological specimen or calculating differences between vectors in the three dimensional coordinate space that defines the image of the biological specimen. The other of the color transformations, a Quantitative Chromatic Transformation (QCT), is a colorimetric transformation that produces three new quantitities from the original red, green, and blue pixel values for each color pixel of an image. These three new quantities, X, Y, and Z can each be related to the quantitative amount of absorbing molecules sampled by that pixel.

Abstract: A method and apparatus for automated cell analysis of biological specimens automatically scans at a low magnification to acquire images which are analyzed to determine candidate cell objects of interest. The low magnification images are converted from a first color space to a second color space. The color space converted image is then low pass filtered and compared to a threshold to remove artifacts and background objects from the candidate object of interest pixels of the color converted image. The candidate object of interest pixels are morphologically processed to group candidate object of interest pixels together into groups which are compared to blob parameters to identify candidate objects of interest which correspond to cells or other structures relevant to medical diagnosis of the biological specimen. The location coordinates of the objects of interest are stored and additional images of the candidate cell objects are acquired at high magnification.

Abstract: Two color transformations, as described herein, facilitate identification of the objects of interest in the biological specimen. One of the color transformations, a Minus Clear Plus One (MC+1) transformation, can be conceptualized as either translating and rotating axes of a three-dimensional coordinate space that defines an image of the biological specimen or calculating differences between vectors in the three dimensional coordinate space that defines the image of the biological specimen. The other of the color transformations, a Quantitative Chromatic Transformation (QCT), is a calorimetric transformation that produces three new quantities from the original red, green, and blue pixel values for each color pixel of an image. These three new quantities, X, Y, and Z can each be related to the quantitative amount of absorbing molecules sampled by that pixel.

Abstract: This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6 receptor agonist compound, wherein said amount is effective to activate the P2Y6 receptors on the luminal surface of lung epithelia. The P2Y6 receptor agonist compounds useful for this invention include mononucleoside 5?-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.

Abstract: The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a compound of Formula II, which is a mixture of cis and trans-diastereomers, and (b) chemically decomposing the compound of Formula II in a solution comprising a solvent and an acid that is a hydrogen donor or an electron pair acceptor, whereby the cis diastereomer is decomposed and the compound of Formula I is obtained. The compounds prepared by the present invention are useful in treating diseases or conditions associated with platelet aggregation and/or platelet activation.

Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.

Abstract: The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation, preferably in a reversible manner. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.